Praxis Precision Medicines Submits Two NDAs, Eyes Commercial Transition
Event summary
- Praxis submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (DEEs) to the FDA in February 2026.
- Company raised $621 million in January 2026, bringing total cash to $926 million as of December 31, 2025.
- Topline results for vormatrigine (focal epilepsy) and elsunersen (SCN2A DEE) expected in H1 2026.
- Praxis added two new board members and promoted key executives in January 2026.
The big picture
Praxis is transitioning from a clinical-stage biotech to a commercial entity, leveraging Breakthrough Therapy Designations to accelerate FDA reviews. The company's $926 million cash position provides runway into 2028, but success hinges on securing approvals and executing launches in competitive CNS markets. The strategic focus on precision neuroscience positions Praxis to capitalize on unmet needs in epilepsy and movement disorders.
What we're watching
- Regulatory Timing
- Whether the FDA will approve ulixacaltamide and relutrigine by late 2026, enabling commercial launch.
- Clinical Pipeline
- The pace at which vormatrigine and elsunersen advance toward potential NDAs in 2027.
- Commercial Execution
- How effectively Praxis scales its commercial organization for ulixacaltamide and relutrigine launches.